The AmoyDx® OncoPro Liquid NGS Panel is a next-generation sequencing (NGS)-based assay designed for the qualitative detection of single nucleotide variants (SNVs), insertions and deletions (InDels), gene fusions, and copy number variations (CNVs) across 152 target genes, as well as for determining tumor microsatellite instability (MSI) status. The panel detects these genetic alterations using circulating cell-free DNA (cfDNA) extracted from plasma, derived from anticoagulated peripheral whole blood samples.
